# Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

> **NCT00943293** · PHASE1 · TERMINATED · sponsor: **University of Chicago** · enrollment: 1 (actual)

## Conditions studied

- Preleukemia
- Myeloproliferative Disorders
- Lymphoma
- Myeloma
- Graft Versus Host Disease

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** Campath

## Key facts

- **NCT ID:** NCT00943293
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-05
- **Primary completion:** 2011-09
- **Final completion:** 2012-01
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Poor accrual; did not enter phase 2
- **Last updated:** 2014-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00943293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00943293, "Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00943293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*